API-Schwierigkeiten activates Laurus Labs-Aktie Trotz CDMO-Erholung

Jefferies was awarded “Underperform” by Laurus Labs Ltd (LAURUS:IN) Company for INR 250.00 for INR 300.00. This research was commissioned as a new analysis data in the two-quarter research of Laurus Labs, called Bereich Contract Development and Manufacturing Organization (CDMO) during the Schwächen of the Active Pharmaceutical Ingredients (API) Segment.

Laurus Labs operates in the fourth quarter of 2025, with the participation of Margen in all types of challenges. Trotz faced a problem at CDMO-Umsatz in the fourth quarter. Laurus Labs Management set the best Umsatzprognose expected from Ziel at 20% EBITDA Margin for the following year.

Jefferies-Analyst noted that the positive trend in the CDMO Segment has a current real positive trend. Gleichzeitig surpassed Gesamtwachstum behind Bereiche von Laurus Labs. The information has a Company Schätzungen for Gewinn for Aktie (EPS) with an increase of 3% between 2025 and 2026. 2% less amount.

Jefferies got an early start on CDMO-Geschritte from Laurus Labs, gaining more from non-performance segments and benefiting from Unternehmens’ Margen. The additional fee of INR 300.00 adds up to a larger amount of Ausblick with the benefits of Laurus Labs.

Diese Übersetzung wurde mithilfe künstlicher Intelligenz erstellt. Learn more about the required information.